Ultimovacs ASA Announces Fourth Quarter 2024 Financial Results
Ultimovacs ASA (OSE: ULTI), a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer, has shared its financial results for the fourth quarter of 2024. The company has reported significant updates and developments that signal its ongoing commitment to advancing cancer treatment options.
Highlights of the Month
Recently, Ultimovacs confirmed an agreement to merge with Zelluna Immunotherapy AS. This partnership aims to create a more robust entity that is better suited to tackle the challenge of cancer treatments. Zelluna Immunotherapy specializes in pioneering T-Cell Receptor Natural Killer (TCR-NK) cell therapies, which are designed for treating solid tumors. Ultimovacs will gain complete ownership of Zelluna and has proposed a private placement to raise additional funding to support this venture.
Plans for Combined Resources
The newly formed company, Zelluna ASA, aims to achieve several critical goals. These include:
- Initiating the world's first clinical studies on the MAGE-A4 targeting TCR-NK program, ZI-MA4-1, focusing on its efficacy against solid cancers.
- Developing a diversified pipeline of TCR-NK therapies.
- Unlocking the potential of the MultiClick technology.
- Completing the UV1 program, which has shown promise in enhancing immunotherapeutic effects.
Financial Overview
Ultimovacs reported a total operating expense of MNOK 121.0 for Q4 2024 and MNOK 223.7 for the entire fiscal year. Notably, a portion of these expenses was attributed to write-downs associated with the UV1 patents and the licenses tied to their TET-technology.
Loss and Cash Flow Implications
The financial results also indicate a total loss of MNOK 107.7 for the last quarter and a year-end total of MNOK 201.1. This has affected the company's cash flow, with a significant net cash outflow of MNOK 24.7 for Q4 2024. Ultimately, Ultimovacs ended the year with a cash balance of MNOK 107.4.
Upcoming Events
As part of its commitment to transparency, Ultimovacs will publish a quarterly report and conduct a conference call to discuss these results in detail. This event is scheduled for the morning of January 31, where stakeholders can ask questions and gain further insights into the company's future directions.
About Ultimovacs
Ultimovacs is a biotechnology innovator devoted to the development of immunotherapies for cancer. Its flagship product candidate, UV1, stands as a promising vaccine designed to activate the immune system against cancer by targeting telomerase—a shared antigen in many cancers.
The company is actively testing UV1 in clinical trials across various types of cancers, including melanoma and non-small cell lung cancer. With over 640 patients enrolled in ongoing clinical programs spanning multiple regions, Ultimovacs is committed to finding effective treatment methodologies for patients battling cancer.
In addition to its core offerings, Ultimovacs is advancing a new conjugation technology, aimed at expanding its vaccine pipeline and potentially applicable to varied therapeutic approaches.
Frequently Asked Questions
What recent developments has Ultimovacs announced?
Ultimovacs announced a merger with Zelluna Immunotherapy AS to enhance its cancer treatment efforts.
What are the key financial results for Q4 2024?
Total operating expenses were MNOK 121.0, with a total loss of MNOK 107.7 for the quarter.
What is the focus of Ultimovacs' research and development?
Ultimovacs focuses on developing immunotherapies against cancer, particularly through its UV1 cancer vaccine.
How does Ultimovacs plan to utilize its recent funding?
The funding will support the development of TCR-NK therapies and advance their existing clinical programs.
What are Ultimovacs' goals with the merger with Zelluna?
They aim to advance innovative therapies and expedite clinical studies in solid cancers.
